romosozumab   Click here for help

GtoPdb Ligand ID: 8092

Synonyms: AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg
Approved drug
romosozumab is an approved drug (Japan, FDA and EMA (2019))
Compound class: Antibody
Comment: Romosozumab is a humanised anti-sclerostin monoclonal antibody that was developed by Amgen and UCB for the treatment of osteoporosis [4-5]. Amgen holds patent protection claiming the polypeptide composition of romosozumab in the US and the EU (expected expiry in 2026).
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
sclerostin Primary target of this compound Hs Antibody Binding 11.2 – 12.2 pKd - 7
⤷ pKd 11.2 – 12.2 (Kd 6x10-12 – 6x10-13 M) [7]
Description: Affinity across a range of antibodies tested, as the lead antibody is not indicated in the patent.